# US 2010/0168416 A1 · Polycyclic heteroaryl substituted triazoles useful as axl inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168416 A1
- Document ID: US20100168416A1
- Status: Published application
- Kind: A1
- Application number: 12/720,448
- Filed: 2010-03-09
- Published: 2010-07-01
- Earliest claimed: 2006-12-29
- Assignees: Rigel Pharmaceuticals, Inc.
- Inventors: Dane Goff; Jing Zhang; Rajinder Singh; Sacha Holland; Jiaxin Yu; Thilo J. Heckrodt; Pingyu Ding; Joane Litvak
- Web page: https://patentgrep.com/patent/US20100168416A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/14: for lactation disorders, e.g. galactorrhoea
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 27/02: Ophthalmic agents
- A61P 27/12: for cataracts
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/14: containing three or more hetero rings
- C07D 451/04: with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/10: Spiro-condensed systems
- C07D 491/04: Ortho-condensed systems
- C07D 491/20: Spiro-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.

## Claims

### Claim 1

A process for preparing an aryl-fused cycloheptanone or a heteroaryl-fused cycloheptanone of formula (i):
wherein Z is an aryl or a heteroaryl and each R1 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, and optionally substituted heteroarylalkyl;
wherein the process comprises:
a) combining a reactant of formula (ii):
wherein each R2 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted aralkyl, and optionally substituted heteroarylalkyl, with a reactant of formula (iii):
wherein Z is the aryl or the heteroaryl, as defined above, and each LG is independently a suitable leaving group, in the presence of a protic solvent, an aprotic solvent, and a base to form a product; and
b) subjecting the product of step a) to a basic hydrolytic media followed by acid to form the aryl-fused cycloheptanone or a heteroaryl-fused cycloheptanone of formula (i).

### Claim 2 (depends on 1)

The process of claim 1, wherein Z is phenyl.

### Claim 3 (depends on 2)

The process of claim 2, wherein each R2 is lower alkyl.

### Claim 4 (depends on 3)

The process of claim 3, wherein each R1 is hydrogen.

### Claim 5 (depends on 4)

The process of claim 4, wherein each LG is halo.

### Claim 6 (depends on 5)

The process of claim 5, wherein the protic solvent is an alcohol.

### Claim 7 (depends on 6)

The process of claim 6, wherein the aprotic solvent is an ether.

### Claim 8 (depends on 7)

The process of claim 7, wherein the base is a metal alkoxide.

### Claim 9 (depends on 8)

The process of claim 8, further comprising exposing the product of step a) to an acidic media prior to step b).

### Claim 10 (depends on 9)

The process of claim 9, wherein step a) is performed within a temperature range of between about −10° C. and about 100° C.

### Claim 11 (depends on 9)

The process of claim 9, wherein step a) is performed within a temperature range of between about 0° C. and about 50° C.

### Claim 12 (depends on 9)

The process of claim 9, wherein step a) is performed within a temperature range of between about 0° C. and about 30° C.

### Claim 13 (depends on 12)

The process of claim 12, wherein the basic hydrolytic media comprises an alcoholic solution of a metal hydroxide or metal alkoxide.

### Claim 14 (depends on 12)

The process of claim 12, wherein the basic hydrolytic media comprises an alcoholic solution of a metal hydroxide.

### Claim 15 (depends on 12)

The process of claim 12, wherein step b) is performed within a temperature range of between about 40° C. and about 150° C.

### Claim 16 (depends on 13)

The process of claim 13, wherein step b) is performed within a temperature range of between about 60° C. and about 100° C.

### Claim 17 (depends on 13)

The process of claim 13, wherein step b) is performed within a temperature range of between about 60° C. and about 100° C.

### Claim 18 (depends on 13)

The process of claim 13, wherein the protic solvent comprises a lower alkanol.

### Claim 19 (depends on 18)

The process of claim 18, wherein the aprotic solvent is THF.

### Claim 20 (depends on 19)

The process of claim 19, wherein each LG is bromo.

### Claim 21 (depends on 20)

The process of claim 20, wherein the acid and the acidic media each independently comprise at least one of an organic acid and an inorganic acid.

### Claim 22 (depends on 20)

The process of claim 20, wherein the protic solvent comprises at least one of methanol and ethanol.

### Claim 23 (depends on 22)

The process of claim 22, wherein the protic solvent is methanol.

### Claim 24 (depends on 23)

The process of claim 23, wherein step a) is performed in about 1:1 methanol to THF.
